9991 Results for "

Cancer Inhibitors

" in MedChemExpress (MCE) Product Catalog:
Products (9991)

9991 Results for "Cancer Inhibitors" in MCE Product Catalog:

1199
1199 Publications Verification
Cat. No.: HY-10108A
CAS No.: 934389-88-5
Purity:  99.93%
Research Areas:  

Cancer

LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC50 values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits CK2 with an IC50 of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .
loading...
    loading...
698
698 Cited Publications
Cat. No.: HY-15142
CAS No.: 25316-40-9
Purity:  99.90%
Synonyms: Hydroxydaunorubicin hydrochloride; ADR
Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; ADR), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .
loading...
    loading...
612
612 Cited Publications
Cat. No.: HY-12041
CAS No.: 129-56-6
Purity:  99.73%
Research Areas:  

Cancer

SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .
loading...
    loading...
551
551 Cited Publications
Cat. No.: HY-100218A
CAS No.: 1219810-16-8
Purity:  99.90%
Synonyms: (1S,3R)-RSL3
RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells .
loading...
    loading...
316
316 Cited Publications
Cat. No.: HY-10431
CAS No.: 301836-41-9
Purity:  99.85%
Research Areas:  

Cancer

SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .
loading...
    loading...
307
307 Cited Publications
Cat. No.: HY-10201
CAS No.: 284461-73-0
Purity:  99.92%
Synonyms: Bay 43-9006
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .
loading...
    loading...
307
307 Cited Publications
Cat. No.: HY-10201A
CAS No.: 475207-59-1
Purity:  99.75%
Synonyms: Bay 43-9006 tosylate
Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .
loading...
    loading...
290
290 Cited Publications
Cat. No.: HY-17026
CAS No.: 95058-81-4
Synonyms: LY 188011
Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, and can modulate autophagy. Gemcitabine induces apoptosis through the activation of p38 MAPK. Gemcitabine demonstrates efficacy in mouse models of pancreatic and breast cancer. Gemcitabine can be used for cancer research, such as pancreatic cancer, non-small cell lung cancer, and breast cancer .
loading...
    loading...
259
259 Cited Publications
Cat. No.: HY-A0281
CAS No.: 1821-12-1
Synonyms: 4-PBA; Benzenebutyric acid
Target:  

HDAC Virus Protease

Research Areas:  

Infection Cancer

4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research.
loading...
    loading...
259
259 Cited Publications
Cat. No.: HY-15654
CAS No.: 1716-12-7
Purity:  99.86%
Synonyms: 4-PBA sodium; 4-Phenylbutyric acid sodium; Benzenebutyric acid sodium
Target:  

HDAC Autophagy Apoptosis

Research Areas:  

Cancer

Sodium 4-phenylbutyrate (4-PBA sodium) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research .
loading...
    loading...
249
249 Cited Publications
Cat. No.: HY-50767
CAS No.: 571190-30-2
Synonyms: PD 0332991
Target:  

CDK

Research Areas:  

Cancer

Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
249
249 Cited Publications
Cat. No.: HY-50767A
CAS No.: 827022-32-2
Synonyms: PD 0332991 monohydrochloride
Target:  

CDK

Research Areas:  

Cancer

Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
245
245 Cited Publications
Cat. No.: HY-A0065
CAS No.: 827022-33-3
Synonyms: PD 0332991 isethionate
Target:  

CDK

Research Areas:  

Infection Neurological Disease Cancer

Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
232
232 Cited Publications
Cat. No.: HY-17371
CAS No.: 61825-94-3
Research Areas:  

Inflammation/Immunology Cancer

Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research .
loading...
    loading...
229
229 Cited Publications
Cat. No.: HY-50767C
CAS No.: 571189-11-2
Synonyms: PD-0332991 hydrochloride
Target:  

CDK

Research Areas:  

Cancer

Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
217
217 Cited Publications
Cat. No.: HY-50895
CAS No.: 184475-35-2
Synonyms: ZD1839
Target:  

EGFR Autophagy Apoptosis

Research Areas:  

Cancer

Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
loading...
    loading...
202
202 Cited Publications
Cat. No.: HY-15772
CAS No.: 1421373-65-0
Purity:  99.92%
Synonyms: AZD-9291; Mereletinib
Target:  

EGFR

Research Areas:  

Cancer

Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .
loading...
    loading...
202
202 Cited Publications
Cat. No.: HY-15772A
CAS No.: 1421373-66-1
Purity:  99.97%
Synonyms: AZD-9291 mesylate; Mereletinib mesylate
Target:  

EGFR

Research Areas:  

Cancer

Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .
loading...
    loading...
201
201 Cited Publications
Cat. No.: HY-15147
CAS No.: 284028-89-3
Purity:  99.80%
Target:  

β-catenin PARP

Research Areas:  

Cancer

XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation .
loading...
    loading...
192
192 Cited Publications
Cat. No.: HY-W008923
CAS No.: 17086-28-1
Doxycycline monohydrate is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline monohydrate is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline monohydrate also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline monohydrate induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline monohydrate also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline monohydrate has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers .
loading...
    loading...